The reported incidence ofskin metastases from lung cancer varies from 2.8-7.5%. In the present study 8.7% of patients had skin metastases, with head and neck being the most common sites, nodular lesions the most common, and adenocarcinoma the most frequent histology. Although most patients develop these lesions during the course of a known progressive disease, they may be the presenting manifestation of a primary tumour in the lung. The occurrence of skin lesions in lung cancer announces an ominous prognosis. The response to chemotherapy is poor, possibly due to poor blood supply to the skin; monitoring response to chemotherapy, however, is easier when such lesions are present.
The commonest tumour to metastasise to the skin in males is lung cancer with a reported incidence of 2.8-7.5%.12 Although the anterior trunk, and head and neck regions are reported to be common sites, skin metastases may arise anywhere on the body. 3 Lung cancer metastasises to almost every organ. Frequent extrathoracic sites include liver, adrenals, bones, brain and kidney.4 Skin metastases, though uncommon, can be the sole manifestation of the disease, and could be a sensitive monitor of response to chemotherapy. 5 Cutaneous metastatic lesions due to lung cancer are physically indistinguishable from those due to carcinoma originating elsewhere in the body. They occur with sufficient frequency and at any site, that lung cancer should always be considered in the differential diagnosis of patients with nodular skin lesions.6
Materials and methods
Medical records of 491 patients with lung cancer at the Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, were studied. Of these 43 patients were found to have cutaneous metastases. Their site, duration, histology and response to therapy were assessed. Skin metastases due to primaries other than lung were excluded. Those with subcutaneous metastases involving lymph nodes or direct extension to the skin ofthe chest wall were excluded from the analysis, as were patients with incomplete medical records. Skin nodules were either biopsied or subjected to fine needle aspiration cytology (FNAG) in all but three patients.
Results
A total of 43 patients were found to have cutaneous metastases (34 men and nine women). Ages ranged from 30 to 85 years (mean 54.5). All except seven patients were smokers. The distribution of the skin lesions were variable. Scalp, head and neck were the most common sites (49%), followed by chest (37%), lower limb (5%), and upper limb (2%). Three patients (7%) had metastases to both head/neck and chest/abdomen (box 1). Skin nodules were the most common manifestation (figures 1 and 2); 11 patients had multiple lesions (box 1). Skin ulceration was not common, only one patient having ulceration on the top of the nodule. Black discolouration of skin was noted in three patients. The size of the nodules was 2-10 cm, average 4 cm. The lesions were firm, nodular, mobile, and large enough to be noted by patients themselves.
Skin metastases were the first clinical manifestation of disease in five patients; preceding endobronchial symptoms by 4-6 Cutaneous metastases are a sign ofan aggressive, poorly differentiated, malignant tumour. Of the various histologies, adenocarcinomas are the most common.5 Four patients in the present study had mucin-secreting adenocarcinomas which are known to follow an aggressive course.
Characteristics of cutaneous metastases in 43 patients
The appearance of a skin nodule provides a valuable tool for monitoring response to chemotherapy.5 The response, however, may be unrelated to the primary tumour, as skin lesions may be less sensitive to chemotherapy due to the relatively poorer blood supply of the skin. After an initial partial response to chemotherapy all lesions in our study progressed and even in patients with small cell lung cancer, a complete response at the cutaneous metastatic site was not observed.
Lung cancer patients with cutaneous secondaries are not likely to be cured. Such metastases signify a fast-growing aggressive primary in the lung. They aid rapid diagnosis when they are the sole manifestation of an occult primary. These patients have an extremely poor prognosis, despite aggressive combinations of chemotherapy and/or radiation therapy. Generally, therefore, only palliative chemotherapy is offered, with or without radiation. The continuation of palliative treatment needs to be balanced between toxicity and benefits obtained. Radiation therapy to the metastatic skin lesion is not indicated unless associated with severe pain or bleeding, which is not common.
We conclude that scalp, head/neck, and chest are the most common sites for skin metastases in lung cancer. They usually present as a cutaneous nodule and their response to chemotherapy is generally poor; due partly to the poor blood supply of the skin. Their recognition, however, is important; every fresh cutaneous lesions should lead to suspicion of a bronchogenic carcinoma, particularly if the patient is a smoker. All such lesions should be biopsied. We also conclude that a cutaneous metastases is the most common dermatological manifestation of lung cancer. 
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